Structure Therapeutics announced positive results from its experimental oral obesity drug, with a weight loss of 6.2% on average in a mid-stage study. This exceeded Wall Street expectations and led to a 32% increase in the company’s shares. The drug aims to capture a share of the $150 billion global obesity treatment market by the early 2030s, competing with injectable drugs from Novo Nordisk and Eli Lilly. In other news, the FDA advisory panel is discussing a therapy using MDMA for PTSD patients, marking a shift in considering psychedelics for medical benefits. Follow the meeting on the STAT blog for updates.
Source link
We’re reading about an FDA meeting on MDMA, a new obesity pill
